Possible 指定 against 株式会社 ヘリオス
For developers: integration details
You do not need this for normal browsing. Use it when integrating this enforcement record into an internal tool or AI workflow.
/api/v1/enforcements?company=%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%E3%83%98%E3%83%AA%E3%82%AA%E3%82%B9&limit=10Action summary
- Company
- 株式会社 ヘリオスJapanese originalOriginal: 株式会社ヘリオス
- Entity match
- Possible entity match60/100Machine extractedCompany name extracted from the Japanese public disclosure
- Governing law
- 薬事法薬事法
- Action type
- 指定指定
- Action date
- 28 February 2017
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
A stem cell product used for the treatment of acute cerebral infarction, derived from adult human (same species) bone marrow multipotent progenitor cells, developed overseas. It is a suspension of adherent stem cells collected and processed from donor bone marrow, with novelty and high breakthrough potential aimed at improving functional impairments caused by acute cerebral infarction.
Show original Japanese text
ヒト（同種）成人骨髄由来多能性前駆細胞を用いた急性期脳梗塞の治療を目的とした幹細胞製品であり、海外で開発されている。ドナーの骨髄から採取・加工した接着性幹細胞の懸濁液であり、急性期の脳梗塞に伴う機能障害の改善を目的とする点に新規性があり、画期性が高い。
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Japanese regulatory disclosure under 薬事法.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Evidence pack
- Extracted at
- 2026-04-25T00:13:59.87+00:00
- Evidence checked
- 2026-04-25T00:13:59.87+00:00
- Archive captured
- 2026-04-07T12:02:12.132+00:00
Show audit JSON
{
"record": {
"id": "d5f18eeb-97d9-4463-aa53-3fc8514c75f9",
"url": "https://regbase.jp/en/enforcement/other-heriosu-20170228",
"company_name_original": "株式会社ヘリオス",
"company_name_registry": "株式会社 ヘリオス",
"corporate_number": null,
"law": {
"ja": "薬事法",
"en": "薬事法"
},
"action_type": {
"ja": "指定",
"en": "指定"
},
"authority": {
"ja": "厚生労働省",
"en": "Ministry of Health, Labour and Welfare"
}
},
"entity_match": {
"status": "possible",
"confidence": 60,
"method": "extracted_japanese_name",
"method_label": "Company name extracted from the Japanese public disclosure",
"notes": null
},
"review": {
"status": "unreviewed",
"label": "Machine extracted"
},
"compliance_context": {
"severity": "Context needed",
"actionMeaning": "This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.",
"practicalNote": "Review the original Japanese source and determine relevance to your counterparty-risk workflow.",
"lawContext": "Japanese regulatory disclosure under 薬事法."
},
"evidence": {
"recordUrl": "https://regbase.jp/en/enforcement/other-heriosu-20170228",
"officialSourceUrl": "https://www.mhlw.go.jp/stf/houdou/0000153128.html",
"archiveUrl": "https://kiroku.today/view/60d0baf7afokk4is",
"archiveCapturedAt": "2026-04-07T12:02:12.132+00:00",
"extractedAt": "2026-04-25T00:13:59.87+00:00",
"translatedAt": "2026-05-01T07:03:47.522+00:00",
"evidenceCheckedAt": "2026-04-25T00:13:59.87+00:00",
"generatedAt": "2026-06-19T10:27:44.452Z"
},
"limitations": [
"RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
"English summaries are provided for reference. The original Japanese source is authoritative.",
"Possible or unresolved entity matches should be manually verified before use in a decision."
]
}The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.